China

Business deal agreement
#Antibody drug conjugate (ADC) #Boehringer Ingelheim #China #Collaboration #Oncology

Boehringer Ingelheim puts China strategy into action with SBP deal

Boehringer Ingelheim and China’s SBP Group have entered a strategic multi-programme agreement with to advance potential cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.   Building on the companies’ existing collaboration in oncology, the agreement will bring together SBP Group’s platforms and early-development capabilities… Read More

#Business & Investment #News

Map of China
#CAR-T #Cell therapy #China #Oncology #Solid tumours

When the world’s first solid-tumour CAR-T gets approved in China

In June 2026, China’s National Medical Products Administration cleared satricabtagene autoleucel (satri-cel), CARsgen’s Claudin18.2 CAR-T, for advanced gastric cancer. It became the world’s first CAR-T cell therapy approved for a solid tumour. The science is genuinely impressive. But the geography is the story. Satri-cel is not a Chinese… Read More

#Exclusive Content #Opinion #Regulatory

#China #GLP-1 #Market reporting #Metabolic diseases #Obesity #Weight loss

How advanced is China in diabetes drug discovery?

With the largest diabetic population and a pedigree in metabolic diseases, China is becoming one to watch in diabetes and obesity drug discovery. Diana Turner finds out about an increasingly competitive market. Research by clinical research organisation ICON in late… Read More

#Exclusive Content

Hepatitis B
#China #Collaboration #hepatitis

Aligos and Xiamen Amoytop agree hepatitis B alliance

Aligos Therapeutics and Xiamen Amoytop Biotech have entered into an exclusive license agreement to develop and commercialise pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.  Under the terms of the agreement, Aligos will receive an upfront milestone of $25 million and is eligible… Read More

#Business & Investment #News

Map of China
#China #Radiopharmaceuticals

Radspherin receives patent protection in China 

The China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, a radiopharmaceutical treating micrometastases in cancer patients.  Radspherin, developed by biotechnology company Oncoinvent, is a receptor-independent alpha radiation therapy that destroys residual micrometastases using a single, highly localised dose of alpha radiation.  … Read More

#News

Map of China
#AstraZeneca #China #Investment #Obesity #Weight loss

AZ expands China operations, agrees obesity deal with CSPC

AstraZeneca has agreed a new strategic collaboration agreement with China’s CSPC Pharmaceuticals to develop multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.   Under this agreement, the companies will initially progress four programmes, which utilise CSPC’s AI-driven peptide drug discovery platform and its LiquidGel… Read More

#Business & Investment #News #Trending News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #China #Kelun-Biotech #NMPA #Oncology #Solid tumours

Kelun-Biotech’s ADC IND for solid tumours approved in China

Kelun-Biotech’s Investigational New Drug (IND) application for SKB105 (CR-003), an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumours.  In December 2025, Kelun-Biotech and… Read More

#News #Regulatory

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

Chinese flag
#AI #Antibody drug conjugate (ADC) #Biotech #China #ICON

China becoming dominant force in biotech sector, survey says 

China is emerging as a ‘global innovation powerhouse’, according to clinical research organisation ICON.  ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.  According to the… Read More

#Business & Investment #News

Map of China
#Artificial intelligence (AI) #China #Metabolic diseases #Oncology

Is China the next global biopharma powerhouse?

Regulatory reform and investment in innovation have supercharged China’s biopharma sector, but will ongoing trade wars with the US pose a risk to growth? By Diana Turner. China’s role in the global biopharma sector has grown significantly in recent years. It is the world’s largest supplier of active… Read More

#Exclusive Content #Market Reports

#China #NMPA #Shingles

NMPA approves shingles vaccines in China

The China National Medical Products Association (NMPA) has approved Shingrix for the prevention of shingles. Shingrix has been approved for the prevention of virus in adults aged 18 years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression.  Shingles is caused… Read More

#News #Regulatory

Heart
#Arrowhead Pharmaceuticals #Cardiometabolic diseases #China #RNA #Sanofi

Sanofi buys Chinese rights to cardiometabolic drug candidate

Sanofi has bought the rights to Arrowhead Pharmaceuticals first-in-class RNA interference (RNAi) therapeutic candidate for hypertriglyceridemia in Greater China.  Under the agreement, Sanofi will pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. … Read More

#Business & Investment #News

Colon cancer
#China #Colorectal cancer #Monoclonal antibodies #Oncology #Pierre Fabre Laboratories

China approval for colorectal cancer combination treatment

The Chinese authorities have granted a marketing authorisation for Pierre Fabre Laboratories’ Braftovi, in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.  The approval is based on the Phase III BEACON CRC trial, which demonstrated a significant… Read More

#News #Regulatory

Leukaemia
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

First Bcl-2 inhibitor approved in China for CLL/SLL

Ascentage Pharma’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).  It is approved in patients who have previously received at least one systemic therapy including Bruton’s tyrosine… Read More

#News #Regulatory